Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer

November 18, 2020
NEW YORK, NY – November 18, 2020 – Elevation Oncology, a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today a Series…

Harmony Biosciences Receives FDA Approval for Expanded Use of WAKIX® (Pitolisant) for the Treatment of Cataplexy in Adult Patients with Narcolepsy

October 13, 2020
WAKIX is the first and only non-scheduled treatment approved for excessive daytime sleepiness or cataplexy in adult patients with narcolepsy PLYMOUTH MEETING, PA and CHICAGO, IL, October 13, 2020 — Harmony…

Spruce Biosciences Announces Pricing of Upsized Initial Public Offering

October 9, 2020
SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced the pricing of its…